ibrutinib,rituximab
abbvie,janssen
[' ibru']
#ash22 | what's new in 1l treatment of #mcl for younger patients? strong efficacy with acceptable toxicity of additional ibrutinib during induction and as maintenance with or without asct. martin dreyling conlusion. #triangletrial 
Latest research in hematology | Breaking news, insights, interviews, live tweeting and updates from major conferences. Co-published @ilpensiero | @think2it